FDA Concludes Successful Inspection of BioPharma Services, Recognizing Excellence in Quality and Safety Following Comprehensive Review

Toronto, ON, September 23 — BioPharma Services Inc., a leading Contract Research Organization (CRO), is proud to announce the successful completion of a GCP inspection by the FDA at our clinical facility. The weeklong audit concluded with no Form 483 issued.  This thorough inspection reinforced our commitment to safeguarding study participants, maintaining data reliability, and upholding the highest standards of integrity in our clinical trial processes. The FDA inspectors conducted a thorough and detailed audit of our operational methods, focusing on the reliability and integrity of our procedures and the overall quality of our work. We are pleased to report that the feedback we received was overwhelmingly positive, as BioPharma continues to build on its impressive track history of zero Form 483 observations.   

“We take immense pride in maintaining the highest quality standards across all areas of our work,” said Vaideki Dharmaratnam, BioPharma’s Senior Director, Global Quality Assurance. “One inspector noted that BioPharma Services demonstrated a meticulous approach to its operations, emphasizing the reliability, integrity, and quality of its procedures. He highlighted the organization’s unwavering commitment to maintaining the highest standards in subject safety and overall work ethics.” 

BioPharma Services remains dedicated to conducting research that meets the stringent requirements of health organizations worldwide. We continuously strive for improvements in the quality of our services and acknowledge the role of the FDA in helping us achieve this mission. Our goal remains to deliver research that is grounded in integrity, quality, and transparency, and ensuring the safety and well-being of all our study participants. 

This inspection reaffirms our commitment to excellence, and we remain dedicated to delivering world-class research with safety and quality as our top priorities. Review BioPharma Services Full Regulatory History Here. 

About BioPharma Services Inc.